Targeted alpha therapy (TAT) is a promising approach for the treatment of cancer and infectious diseases. The availability of suitable alpha emitting isotopes in clinically relevant amounts is a main prerequisite for further development of TAT and its widespread clinical application. Several alpha emitting isotopes have been proven effective in pre-clinical studies and/or clinical trials, including 225Ac / 213Bi, 230U / 226Th, 227Th / 223Ra, 212Pb / 212Bi, 211At and 149Tb. Here we give an overview on methods for the production of these nuclides, describe advantages and limitations of the various processes and give an outlook on future availability and isotope supply.
MORGENSTERN Alfred;
ABBAS Kamel;
BRUCHERTSEIFER Frank;
APOSTOLIDIS Christos;
2008-11-07
BENTHAM SCIENCE PUBL LTD
JRC48527
1874-4710,
http://www.bentham.org/crp/contabs/crp%201-3.htm#3,
https://publications.jrc.ec.europa.eu/repository/handle/JRC48527,
| Name | Country | City | Type |
|---|
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Datasets
| ID | Title | Public URL |
|---|
Dataset collections
| ID | Acronym | Title | Public URL |
|---|
Scripts / source codes
| Description | Public URL |
|---|
Additional supporting files
| File name | Description | File type |
|---|